Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
11 05 2021
Historique:
received: 07 09 2020
accepted: 31 03 2021
entrez: 12 5 2021
pubmed: 13 5 2021
medline: 28 5 2021
Statut: epublish

Résumé

The mechanism by which anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC) is unknown. In this study, we characterize the immune contexture of invasive lung ADC and its precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and multiplex immunofluorescence (mIF). Our results demonstrate that anti-tumor immunity evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive ADC and frankly invasive lung ADC with a gradually less effective and more intensively regulated immune response including down-regulation of immune-activation pathways, up-regulation of immunosuppressive pathways, lower infiltration of cytotoxic T cells (CTLs) and anti-tumor helper T cells (Th), higher infiltration of regulatory T cells (Tregs), decreased T cell clonality, and lower frequencies of top T cell clones in later-stages. Driver mutations, chromosomal copy number aberrations (CNAs) and aberrant DNA methylation may collectively impinge host immune responses and facilitate immune evasion, promoting the outgrowth of fit subclones in preneoplasia into dominant clones in invasive ADC.

Identifiants

pubmed: 33976164
doi: 10.1038/s41467-021-22890-x
pii: 10.1038/s41467-021-22890-x
pmc: PMC8113327
doi:

Substances chimiques

Neoplasm Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2722

Subventions

Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234629
Pays : United States

Références

World J Pediatr. 2020 Feb;16(1):19-30
pubmed: 30796732
Immunity. 2014 Dec 18;41(6):960-72
pubmed: 25526309
Cancer Res. 2001 Nov 1;61(21):7950-4
pubmed: 11691817
Am J Clin Pathol. 1999 May;111(5):610-22
pubmed: 10230351
Oncotarget. 2017 Mar 28;8(13):21994-22002
pubmed: 28423542
Immunogenetics. 2015 Nov;67(11-12):641-50
pubmed: 26416257
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Curr Protoc Mol Biol. 2011 Apr;Chapter 25:Unit25B.10
pubmed: 21472696
Genome Med. 2016 Mar 30;8(1):33
pubmed: 27029192
Trends Immunol. 2001 Aug;22(8):450-7
pubmed: 11473835
Cancer Res. 2017 Nov 15;77(22):6119-6130
pubmed: 28951454
Clin Lung Cancer. 2013 Sep;14(5):521-6
pubmed: 23786997
Nat Commun. 2020 Jan 30;11(1):603
pubmed: 32001676
J Immunother Cancer. 2018 Jun 6;6(1):48
pubmed: 29871672
Cancer Discov. 2017 Oct;7(10):1088-1097
pubmed: 28733428
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Ann Thorac Surg. 2010 Dec;90(6):1759-64
pubmed: 21095303
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
Am J Respir Crit Care Med. 2007 Apr 1;175(7):712-9
pubmed: 17185647
Nature. 2019 Jul;571(7766):570-575
pubmed: 31243362
Nat Med. 2000 Jul;6(7):782-9
pubmed: 10888927
Nature. 1986 Aug 28-Sep 3;322(6082):831-4
pubmed: 2427956
Clin Cancer Res. 2010 Apr 15;16(8):2418-26
pubmed: 20371677
Science. 2014 Oct 10;346(6206):256-9
pubmed: 25301631
J Pathol. 2017 Jan;241(1):10-24
pubmed: 27770445
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Genome Biol. 2020 Nov 4;21(1):271
pubmed: 33148332
Blood. 2005 Apr 1;105(7):2828-35
pubmed: 15572590
Nature. 1998 Sep 3;395(6697):89-93
pubmed: 9738504
Bioinformatics. 2003 Jul 1;19(10):1236-42
pubmed: 12835267
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
N Engl J Med. 2013 Sep 5;369(10):910-9
pubmed: 24004118
Cell Mol Immunol. 2011 Jan;8(1):59-66
pubmed: 21200385
Cancer Res. 2014 Dec 1;74(23):6771-83
pubmed: 25297630
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
J Thorac Oncol. 2019 Nov;14(11):1912-1923
pubmed: 31446140
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
PLoS One. 2011;6(8):e23332
pubmed: 21829728
Immunology. 2007 May;121(1):1-14
pubmed: 17386080
Cancer J. 2020 Nov/Dec;26(6):517-524
pubmed: 33298723
Nat Commun. 2019 Jul 5;10(1):2978
pubmed: 31278276
Mod Pathol. 2018 Jun;31(6):947-955
pubmed: 29410488
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Georgian Med News. 2018 Mar;(276):107-112
pubmed: 29697392
Nat Commun. 2019 Sep 19;10(1):4278
pubmed: 31537801
J Allergy Clin Immunol. 2007 Aug;120(2):247-54
pubmed: 17666214
Int J Mol Sci. 2020 Mar 30;21(7):
pubmed: 32235561
Science. 2003 Apr 18;300(5618):455
pubmed: 12702868
J Thorac Oncol. 2010 Apr;5(4):466-71
pubmed: 20357616
J Immunother Cancer. 2015 Dec 15;3:42
pubmed: 26674611
J Mol Med (Berl). 2001 Aug;79(8):419-27
pubmed: 11511972
Cancer Prev Res (Phila). 2019 Feb;12(2):69-78
pubmed: 30606719
J Virol. 2011 Sep;85(17):8702-8
pubmed: 21715501
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
Cancers (Basel). 2011 Mar 29;3(2):1672-90
pubmed: 24212778
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Immunol Rev. 2008 Apr;222:129-44
pubmed: 18363998
Cancer Discov. 2019 Jun;9(6):722-737
pubmed: 31015319
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Oncogene. 2013 Apr 4;32(14):1743-51
pubmed: 22751118
Clin Lung Cancer. 2003 Jul;5(1):46-62
pubmed: 14596704
J Leukoc Biol. 2015 Jan;97(1):31-8
pubmed: 25360000
Methods Mol Biol. 2020;2055:467-495
pubmed: 31502166
Nat Commun. 2021 Jan 29;12(1):687
pubmed: 33514726
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Trends Cell Biol. 2020 Sep;30(9):695-704
pubmed: 32624246
BMC Mol Biol. 2006 Jan 31;7:3
pubmed: 16448564

Auteurs

Hitoshi Dejima (H)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Xin Hu (X)

Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Runzhe Chen (R)

Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jiexin Zhang (J)

Department of Bioinformatics & Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Junya Fujimoto (J)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Edwin R Parra (ER)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cara Haymaker (C)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Shawna M Hubert (SM)

Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Dzifa Duose (D)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Luisa M Solis (LM)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Dan Su (D)

Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

Junya Fukuoka (J)

Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Kazuhiro Tabata (K)

Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Hoa H N Pham (HHN)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Nicholas Mcgranahan (N)

Cancer Research United Kingdom-University College London Lung Cancer Centre of Excellence, London, UK.

Baili Zhang (B)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jie Ye (J)

Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lisha Ying (L)

Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Zhejiang Cancer Research Institute, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

Latasha Little (L)

Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Curtis Gumbs (C)

Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Chi-Wan Chow (CW)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Marcos Roberto Estecio (MR)

Department of Epigenetics and Molecular Carcinogenesis, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Center of Cancer Epigenetics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Myrna C B Godoy (MCB)

Department of Thoracic Imaging, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mara B Antonoff (MB)

Department of Thoracic and Cardiovascular Surgery, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Boris Sepesi (B)

Department of Thoracic and Cardiovascular Surgery, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Harvey I Pass (HI)

Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, NY, USA.

Carmen Behrens (C)

Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jianhua Zhang (J)

Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ara A Vaporciyan (AA)

Department of Thoracic and Cardiovascular Surgery, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

John V Heymach (JV)

Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Paul Scheet (P)

Department of Epidemiology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

J Jack Lee (JJ)

Department of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jia Wu (J)

Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

P Andrew Futreal (PA)

Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Alexandre Reuben (A)

Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. AReuben@mdanderson.org.

Humam Kadara (H)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. HKadara@mdanderson.org.

Ignacio I Wistuba (II)

Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. IIWistuba@mdanderson.org.

Jianjun Zhang (J)

Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. JZhang20@mdanderson.org.
Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. JZhang20@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH